"Express Mail" mailing label numberE	CV 392094605 US
Date of Deposit 08 July	2004
I hereby certify that this paper or fee is being	deposited with the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 C.F.R. 1.10 on t	the date indicated above and is addressed to the Commissioner for Patents, P.O.
Box 1450, Alexandria, VA_ 22313-1450.	1/2 1/2 1
Box 1450, Alexandria, VA 22313-1450.	Queen Shomer
Printed Name	Signature /

## <u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Thomas Patrick Burris

For:

METHOD OF TREATING ATHEROSCLEROSIS AND

**HYPERCHOLESTEROLEMIA** 

Docket No.:

X-14934

## <u>INFORMATION DISCLOSURE STATEMENT</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicant submits an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Francis O. Ginah

Attorney for Applicants Registration No. 44,712

Phone: 317-276-9477

Eli Lilly and Company Patent Division P.O. Box 6288

Indianapolis, Indiana 46206-6288

re 24, 2004



Sheet 1 of 1

FORM PTO 1449 (modified)	Atty. Docket No. X-14934	Serial 10 / 500 9 1 2		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Thomas Patrick Burris			
	Filing Date	Group .		

			J. <b>S</b> .	PATENT DO	CUMIE	1412				
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if known)		Publication Date MM-DD-YYYY		* *		Pages, Columns, Lines Where Relevant Pages or Relevant Figures Appear		
<u> </u>	AA									
	AB	· · · · · · · · · · · · · · · · · · ·							•	
		FOR	EI(	GN PATENT	DOCU	MENT				
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T <sup>6</sup>	
		Kind Code5 (if known)								
	BA	WO 95 08532	March 30, 1995		Clader, et al.					
	ВВ	BB WO 00 54759 Septemb 2000		ptember 21, 00	Tularik,	Inc.				
٠.	BC	WO 00 30632	June 2, 2000		Balaji, et al.					
· .	BD	WO 98 47509	October 29, 1998		Connolly, et al.			-		
	BE			*						
		NON P	ATE	NT LITERAT	URE DOC	CUMEN	TS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.								
	CA	Heek Van M., et al., "Comparison of the Activity and Disposition of the Novel Cholesterol Absorption Inhibitor, SCH58235, and Its Glucuronide, SCH60663,"  British Journal of Pharmacology, Basingstoke, Hants, GB, Vol. 129, No. 8, pgs. 1748-1754, (2000); XP001057494								
	СВ	Farb, A., et al., "Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent," Circulation, Vol. 104, No. 4, pgs. 473-479, (2001); XP002244114								
	СС	Ward, D., et al., "Drug-eluting stents: an end to restenois as we know it?" Heartwise,  The Irish Heart Foundation's Magazine, Vol. 6, No. 1, pgs. 14-16; XP002244064								
· · · · · · · · · · · · · · · · · · ·	CD									
Examiner Signature				·	Date Cons	idered		L		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.